Description: Regeneus Ltd is a clinical-stage regenerative medicine company. The Company is engaged in developing cell-based therapies for human and animal health markets, with a focus on osteoarthritis and musculoskeletal disorders, as well as oncology and dermatology diseases. The Company's portfolio of therapeutic products is being developed using stem cell and immune oncology technology platforms. The Company's technology platform includes approximately three platforms across both human and animal health businesses, including Human and animal adipose-derived mesenchymal stem cells (MSCs) for the treatment of musculoskeletal diseases; Human and animal immunotherapy personalized cancer vaccine for the treatment of various cancers, and Stem cell secretions cell free supernatant (CFS) technology harnessing the therapeutic potential of mesenchymal stem cells for skincare treatments. The Company's products include Kvax, CryoShot, Progenza, Human Cancer Vaccine and Secretions Cream.
Home Page: regeneus.com.au
RGS Technical Analysis
Allianz Funds
,
Phone:
1300 995 098
Officers
| Name | Title |
|---|---|
| Mr. Karolis Rosickas | Chief Exec. Officer |
| Prof. Graham Vesey Ph.D. | Chief Scientific Officer & Exec. Director |
| Dr. Charlotte Morgan Ph.D. | Head of R&D |
| Ling Leung Hang | Company Sec. |
Exchange: AU
Country: AU
Currency: Australian Dollar (A$)
| GIC Sector: | Health Care |
|---|---|
| GIC Group: | Pharmaceuticals, Biotechnology & Life Sciences |
| GIC Industry: | Biotechnology |
| GIC Sub-Industry: | Biotechnology |
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 13.6854 |
| Price-to-Sales TTM: | 28.0168 |
| IPO Date: | |
| Fiscal Year End: | June |
| Full Time Employees: | 0 |